PRAK Antibody (A-7): sc-46667

PRAK Antibody (A-7) is a mouse monoclonal IgG1 kappa light chain antibody that detects PRAK protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). PRAK (A-7) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. PRAK, also known as p38-regulated/activated kinase or mitogen-activated protein kinase (MAPK)-activated protein kinase (MAPKAPK)-5, is a serine/threonine kinase that is widely expressed and plays a crucial role in cellular responses to stress. PRAK is primarily regulated by p38α and p38β MAP kinases, which activate PRAK in response to stress-related extracellular stimuli such as ultraviolet light, oxidative stress, and proinflammatory cytokines. PRAK phosphorylation is essential for function, as PRAK has been shown to specifically phosphorylate heat shock protein 27 (HSP27) in vitro, indicating involvement in stress-induced phosphorylation of small heat shock proteins in vivo. Understanding PRAK′s role in cellular stress responses is vital, as PRAK may contribute to the development of therapeutic strategies targeting stress-related diseases.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

PRAK Antibody (A-7) References:

1. Regulation of PRAK subcellular location by p38 MAP kinases.  |  New, L., et al. 2003. Mol Biol Cell. 14: 2603-16. PMID: 12808055
2. MAPKAP kinase-2; a novel protein kinase activated by mitogen-activated protein kinase.  |  Stokoe, D., et al. 1992. EMBO J. 11: 3985-94. PMID: 1327754
3. PRAK is essential for ras-induced senescence and tumor suppression.  |  Sun, P., et al. 2007. Cell. 128: 295-308. PMID: 17254968
4. Transgenic mice expressing constitutive active MAPKAPK5 display gender-dependent differences in exploration and activity.  |  Gerits, N., et al. 2007. Behav Brain Funct. 3: 58. PMID: 17997833
5. Determinants that control the distinct subcellular localization of p38alpha-PRAK and p38beta-PRAK complexes.  |  Li, Q., et al. 2008. J Biol Chem. 283: 11014-23. PMID: 18268017
6. PRAK suppresses oncogenic ras-induced hematopoietic cancer development by antagonizing the JNK pathway.  |  Yoshizuka, N., et al. 2012. Mol Cancer Res. 10: 810-20. PMID: 22665523
7. The essential role of PRAK in tumor metastasis and its therapeutic potential.  |  Wang, Y., et al. 2021. Nat Commun. 12: 1736. PMID: 33741957
8. The PRAK-NRF2 axis promotes the differentiation of Th17 cells by mediating the redox homeostasis and glycolysis.  |  Zhao, Z., et al. 2023. Proc Natl Acad Sci U S A. 120: e2212613120. PMID: 37126714
9. Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine.  |  Raingeaud, J., et al. 1995. J Biol Chem. 270: 7420-6. PMID: 7535770
10. Identification of mitogen-activated protein (MAP) kinase-activated protein kinase-3, a novel substrate of CSBP p38 MAP kinase.  |  McLaughlin, MM., et al. 1996. J Biol Chem. 271: 8488-92. PMID: 8626550
11. MAPKAPK5, a novel mitogen-activated protein kinase (MAPK)-activated protein kinase, is a substrate of the extracellular-regulated kinase (ERK) and p38 kinase.  |  Ni, H., et al. 1998. Biochem Biophys Res Commun. 243: 492-6. PMID: 9480836
12. PRAK, a novel protein kinase regulated by the p38 MAP kinase.  |  New, L., et al. 1998. EMBO J. 17: 3372-84. PMID: 9628874

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-PRAK Antibody (A-7) has 17 citations in a variety of scientific publications.

Primary antibodies like Anti-PRAK Antibody (A-7) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

PRAK Antibody (A-7) Specifications

Alternate Product Name: PRAK

Product Clone Name: A-7

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 294-473

Epitope Target: PRAK

Epitope Species: human

Product Reactivity/Detection: PRAK

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 17 citations in various scientific publications

Available Conjugates/Forms for PRAK Antibody (A-7): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin